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Purpose: Women with human papilloma virus (HPV)-associated cervical neoplasia have 
a higher risk of developing breast cancer than the general female population. The pur-
pose of this study was to (i) identify high-risk HPVs in cervical neoplasia and subsequent 
HPV positive breast cancers which developed in the same patients and (ii) determine if 
these HPVs were biologically active.
Methods: A range of polymerase chain reaction and immunohistochemical techniques 
were used to conduct a retrospective cohort study of cervical precancers and subse-
quent breast cancers in the same patients.
results: The same high-risk HPV types were identified in both the cervical and breast 
specimens in 13 (46%) of 28 patients. HPV type 18 was the most prevalent. HPVs 
appeared to be biologically active as demonstrated by the expression of HPV E7 proteins 
and the presence of HPV-associated koilocytes. The average age of these patients diag-
nosed with breast cancer following prior cervical precancer was 51 years, as compared 
to 60 years for all women with breast cancer (p for difference = 0.001).
conclusion: These findings indicate that high-risk HPVs can be associated with cervical 
neoplasia and subsequent young age breast cancer. However, these associations are 
unusual and are a very small proportion of breast cancers. These outcomes confirm and 
extend the observations of two similar previous studies and offer one explanation for the 
increased prevalence of serious invasive breast cancer among young women.
Keywords: breast cancer, cervical neoplasia, human papilloma viruses, young age
inTrODUcTiOn
Women with squamous or glandular precancer of the cervix have a significantly higher risk of sub-
sequent breast cancer than the general female population – odds ratios 1.10 and 1.52, respectively 
(1). Women with human papilloma virus (HPV)-associated cervical neoplasia may some years later 
develop HPV-associated breast cancer (2, 3).
Although these data indicate that HPVs may have a possible role in some breast cancers, it is unlikely 
that HPVs have a major causal role. There are two reasons for this view: (i) in immunocompromised 
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patients (due to either human immunodeficiency viral infections 
or post organ transplantation therapy), there is no increased 
prevalence of breast cancer, which is in contrast to the twofold to 
sixfold increased prevalence of HPV-associated cervical cancer 
in these patients (4), and (ii) the HPV viral load in breast cancer 
is extremely low (5, 6).
Data from The Cancer Genome Atlas (TCGA), published 
on line by the Larsson Lab (6), indicate a low prevalence of 
high cancer risk HPVs in breast cancer. It has been shown that 
approximately 1.3% of these data are contaminated by HPV 18 (7, 
Cantalupo, 2015, personal communication).
There is an apparent conflict between (i) data which indicate 
an increased risk of breast cancer among women with prior 
HPV-associated cervical pathology (1–3) and (ii) the very low 
prevalence of high-risk HPVs in breast cancer as shown in the 
analyses of the TCGA breast cancer data (6). Therefore, there 
is value in confirming by modern molecular methods that the 
two previous studies which demonstrated that some women 
with HPV-associated cervical cancer could subsequently develop 
same type HPV positive breast cancer (2, 3) and in determining if, 
despite their extremely low concentration, HPVs in breast cancer 
are biologically active and have potential oncogenic influences. 
HPV biological activity can be assessed in three ways (i) by the 
identification of HPV transcripts (RNA transcripts have been 
identified in the TCGA analyses referred to above), (ii) expression 
of the HPV oncogenic protein HPV E7 in breast cancers, and (iii) 
the identification of HPV-associated koilocytes in breast cancer.
The purpose of this study was to (i) identify high-risk HPVs 
in cervical neoplasia and subsequent HPV positive breast cancers 
which developed in the same patients and (ii) determine if these 
HPVs were biologically active.
research aPPrOaches, MaTerials 
anD MeThODs
research approaches
We used the following research approaches: (i) a retrospective 
cohort study of women with breast cancer who had prior pre-
cancer or neoplasia of the cervix, (ii) a study of HPV-associated 
biomarkers in these breast cancers to determine if the HPVs were 
biologically active, and (iii) identification of koilocytes by light 
microscopy. We also compared the outcomes of these studies with 
normal breast tissues from women who had not developed breast 
cancer after approximately 10 years.
Patients and specimens
All cervical and subsequent breast cancer specimens were from 
women residing in Australia. We reviewed approximately 4,000 
pathology reports of breast cancer and identified 28 patients who 
had either HPV cervical infections or more commonly cervical 
intraepithelial neoplasia (CIN) 1–11  years prior to developing 
breast cancer. Archival formalin-fixed specimens from these 
patients were identified and collected from a large Australian 
pathology service (Douglass Hanly Moir – Pathology).
Eighteen unselected archival formalin-fixed “normal” breast 
specimens from women who had breast reduction surgery were 
used as a comparison group. Normal breast specimens from 
these women do not provide a strict control group as there is 
no information available about their cervical tissues, although 
cervical HPV infections are likely to be present in some of these 
women (8). While it is possible “normal” breast tissues from 
breast reduction or enhancement are not necessarily normal, they 
are not malignant (9). These donors were followed for 10 or more 
years via the New South Wales State Cancer Registry and none 
had developed breast cancer.
Cohort Studies
We sought to identify HPV DNA sequences in prior cervical neo-
plasia and later breast cancer specimens from the same patients to 
determine if the same HPV virus was present. If the HPV DNA 
was of the same type and sequences in both the prior cervical as in 
the later breast cancer tissues from the same subject, this provides 
potential evidence of prior HPV infection as a possible cause for 
malignancy in the breast.
Preparation of genomic Dna
For standard and quantitative polymerase chain reaction (PCR), 
genomic DNA (gDNA) was extracted from formalin-fixed 
paraffin-embedded (FFPE) breast and cervix tissues using a 
combination of heat treatment and a DNA extraction kit (DNeasy 
Blood and tissue extraction, QIAGEN). The method is described 
in Steinau et al. (10). DNA extraction was conducted according 
to the manufacturer’s recommendation.
A blank extraction control (an extraction without FFPE 
tissues) was performed during the DNA extraction procedure. 
The gDNA extracts were quantified with a NanoDrop spec-
trophotometer (Thermo Scientific). The quality of gDNA was 
assessed by amplification of human β-actin. The primers used 
were β-actin5′_fwd (5′-CTTCTGCCGTTTTCCGTAGG-3′) 
and β-actin3′_rev (5′-TGGGATGGGGAGTCTGTTCA-3′) at 
the final concentration of 1 μM. Thermal cycles were 94°C for 
15 min; 94°C for 30 s, 55°C for 30 s, and 72°C for 45 s for 30 cycles. 
HotStarTaq Master Mix Kit (QIAGEN) was used for PCR master 
mix. gDNA samples, which were β-actin positive, were selected 
for the detection of HPV genomes.
Polymerase Chain Reaction
Both semi-nested PCR and real-time quantitative PCR were used 
for the detection of HPV. Archival DNA is fragmented and the 
original nested MY/Gp primers, in the L1 gene, did not always 
give sound results due to the length of the MY product. Therefore, 
a semi-nested PCR, MY11 to Gp6, followed by Gp5–Gp6 was 
used. Some of the primers have been altered slightly and are 
degenerate for HPV16 and 18. They are also capable of bringing 
up types 3, 11, 12, 45, 58, 73, and 75.
MY11 – (5′GCACAGGGYCAYAAYAATGG3′)
Gp5 – (5′TATTTGTTACTGTKGTWGATAC3′)
Gp6 – (5′GACATGKKGAGGAATATGATT3′)
Positive PCR products were routinely sequenced in addition to 
the negative controls, to ensure there was no contamination. The 
negative controls were no DNA (water) and a blank extraction 
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(which tested the reagents), plus sequencing of the products 
of these controls in case the bands could not be seen on a gel. 
Negative outcomes of PCR analyses of selected breast cancer 
specimens provided negative controls based on breast tissues.
real-Time Pcr
The HPV L1 gene in gDNA samples was amplified using a real-
time PCR machine (Rotor Gene Q, QIAGEN). Thermal cycles 
used were 95°C for 5 min, 95°C for 10 s, and 60°C for 30 s for 60 
cycles. The PCR reaction mix was the Quanti Fast SYBR Green 
kit (QIAGEN) and was used according to the manufacturer’s 
recommendation. The primers used for detection of HPV were 
GP05+ forward (5′TTTGTTACTGTGGTAGATACTAC3′); and 
GP06+ reverse (5′AAATCATATTCCTCMMCATGTC3′) at the 
final concentration of 1 μM.
The quantity of gDNA used for PCR was determined by 
estimating theoretical gene copies of HPV 16 in breast and breast 
cancer tissues (5). A positive control for HPV was a purified PCR 
product containing the HPV L1 region. It was amplified with 
MY11 and MY09 primers. Negative controls were (i) ultrapure 
H2O (no DNA template) and (ii) extraction blank (a DNA extrac-
tion control without FFPE tissues).
Polymerase chain reaction products were analyzed and 
selected for sequencing based on amplification profiles and the 
achievement of the known melting point (the specific tempera-
ture for each product). The analysis was performed using Rotor 
Gene Q software (QIAGEN).
independent confirmation of the Pcr-
Based Outcomes
DNA extracts from 11 selected (for positive HPV) cervical precan-
cer and breast cancer specimens were independently analyzed for 
the presence of HPV DNA (Annika Antonnson, QIMR Berghofer 
Medical Research Institute), using methods as described in Ref. 
(11). Different methods to those described above were used for 
these confirmatory analyses (11).
sequencing the Pcr Products and 
identification of hPV Types
The HPV PCR products from GP5 to Gp6 were sequenced to 
determine the HPV type. The HPV genotypes were identified by 
BLAST via the US National Center for Biotechnology Information.
In situ Pcr
Archival tissues on slides were washed in xylene to remove the 
wax followed by washes in decreasing concentrations of alcohol. 
The tissues were subjected to pepsin digestion with varying times 
of digestion which were required for different tissues. These dif-
ferences were probably due to fixation procedures, which could 
vary in duration. The digestion was stopped in 0.1M Tris buffer 
pH 8. Approximately 75 μl of PCR mix, containing inner nested 
PCR primers Gp5–Gp6. Digoxogenin (DIG) – dUTP (0.3 nM) 
(Roche) – was added to the tissue in a frame which was sealed. 
PCR cycling was the same as for standard PCR. Detection 
using Anti-DIG AP-Fab fragments (1  μl) (Roche) in buffer 
pH 7.5 followed by NBT/BCIP (2 μl) (Roche) in buffer pH 9.5 
was stopped when a blue color was observed in the cells of the 
cancer specimen and not in the negative control. The tissues were 
counterstained with eosin. We used stringent negative controls 
that included omitting both DNA primers and Taq polymerase 
when conducting in situ PCR. Any specimens that were positive 
in the negative controls showed that the DNA was self-priming 
and were unsuitable for in situ work (this is probably due to frag-
mented DNA acting as primers). These samples were eliminated 
from the study. Negative specimens were subjected to beta-globin 
in situ PCR to confirm the result.
Identification of HPVs
The identification of HPV in normal and benign breast or breast 
cancer specimens was considered as positive if two or more of 
the following outcomes in the same specimen were observed: (i) 
HPV DNA sequences identified by standard PCR and/or real-
time PCR and (ii) HPV positive in situ PCR.
HPV Biological Activity
An assessment of HPV biological activity can be conducted in 
several ways: (i) the identification of HPV oncoprotein E7 and (ii) 
the identification of HPV-associated koilocytes.
immunohistochemistry
Antibodies specific for HPV E7 proteins, have recently been 
developed and were used in this study. These antibodies were 
HPV E7 monoclonal “Cervimax” – Valdospan GmbH. Austria 
(12, 13). Standard manual immunohistochemistry (IHC) meth-
ods were used to identify HPV E7 proteins, with the omission 
of the antigen retrieval step. The specificity of these antibodies 
has been demonstrated experimentally and by epidemiological 
studies (12, 13). The HPV E7 antibody reacts with a wide range 
of HPV types, including high risk for cancer HPV 16 and 18. 
HPV E7 antibodies have not been previously used on breast tis-
sues. Good outcomes for both HPV E7 were achieved with clear 
staining of both cytoplasm and nuclei of breast cancer cells with 
1:100, or 1:50 dilution of the antibody without antigen retrieval 
(antigen retrieval involves heating of the specimens at 95°C). 
Positive controls for the E7 antibody were the HeLa (HPV18) cell 
line and cervical tissues that were positive for HPV sequences by 
PCR and sequencing. Freshly cut slides and the cell lines needed 
lesser antibody (1/500 for 30  min) than recommended by the 
manufacturer (Valdospan). Slides that were up to 5  years old 
needed 1/100 dilution of antibody for 1 h.
Histology
The identification of koilocytes by light microscopy is subjective. 
For this reason, two independent observers (James S. Lawson and 
Warick Delprado) reviewed all the specimens and assessed the 
presence of koilocytes.
statistics
The SPSS statistical package was used to (i) assess the significance 
of any differences in outcomes for the various investigations and 
(ii) assess for correlation of non-parametric data.
Patient age Diagnosis hPV e7 hPV
immunohistochemistry Pcr 
consolidated
26. Cervix 44 CIN3 Neg
Breast 45 IDC Gr3 Neg
27. Cervix 44 Normal HPV 18
Breast 48 DCIS 3+ HPV 18
28. Cervix 50 HPV koilos HPV 18
Breast 61 IDC Gr1 Neg HPV 16/18
PCR and immunohistochemistry results using different techniques for patients 1–28.
CIN, cervical intraepithelial neoplasia; DCIS, ductal carcinoma in situ; IDC, invasive 
ductal carcinoma; ILC, invasive lobular carcinoma; Gr, grade.
Genomic extractions were tested for PCR availability before proceeding to screen for 
HPV. Not all extractions were successful. A different extraction was used for the real-
time PCR. Not all specimens were suitable for in situ PCR.
TaBle 1 | continuedTaBle 1 | hPV identification in cervical neoplasia and subsequent breast 
cancer.
Patient age Diagnosis hPV e7 hPV
immunohistochemistry Pcr 
consolidated
1. Cervix 46 CIN1 HPV 16/18
Breast 48 IDC Neg HPV 18
2. Cervix 60 Normal Neg
Breast 66 IDC Gr3 Neg HPV 18
3. Cervix 62 CIN1 HPV 18
Breast 73 DCIS 2+ HPV 18
4. Cervix 53 CIN3 HPV 18
Breast 62 IDC Gr2
5. Cervix 44 CIN2 HPV 18
Breast 45 IDC Gr2 Neg HPV 18
6. Cervix 42 HPV koilos Neg
Breast 47 IDC Gr2 3+ HPV 18
7. Cervix 39 CIN3
Breast 45 ILC Gr2 3+ Neg
8. Cervix 40 CIN3 HPV 18
Breast 45 IDC Gr3 3+ HPV 18
9. Cervix 33 CIN2 HPV 18
Breast 39 IDC Gr2 3+ HPV 18
10. Cervix 44 HPV koilos HPV 18
Breast 44 DCIS Neg HPV 18
11. Cervix 57 HPV koilos HPV 18
Breast 68 IDC Gr3 Neg HPV 18
12. Cervix 43 CIN3 HPV 16/18
Breast 45 IDC Gr2 HPV 18
13. Cervix 29 CIN 2 HPV 16
Breast 32 IDC 3+ HPV 18
14. Cervix 46 HPV koilos HPV 18
Breast 47 IDC Gr2 1+ HPV 18
15. Cervix 41 CIN1
Breast 46 IDC Gr1 2+ HPV 18
16. Cervix 41 CIN2 HPV 16/18/58
Breast 50 IDC Gr2 1+ HPV 58
17. Cervix 33 CIN3 HPV 18
Breast 34 IDC Gr3 Neg HPV 18
18. Cervix 29 HPV koilos Neg
Breast 38 I Muc C Gr2 HPV 16/18
19. Cervix 55 CIN1
Breast 62 IDC Gr1 2+ HPV 18
20. Cervix 57 CIN1 HPV 18
Breast 67 IDC Gr1 1+ HPV 16/18
21. Cervix 36 CIN1 Neg
Breast 40 IDC Gr1 1+ Neg
22. Cervix 54 CIN1 HPV
Breast 64 IDC Gr2 2+ HPV 18
23. Cervix 39 CIN2 HPV
Breast 47 ILC Gr2 1+ Neg
24. Cervix 46 CIN3 HPV 16/18
Breast 52 IDC Gr1 Neg HPV 18
25. Cervix 53 CIN1 HPV 18
Breast 61 IDC Gr2/
DCIS
3+ Neg
(Continued)
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resUlTs
hPV identification in cervical and Breast 
Pathology in the same australian Patients
The same high-risk HPV types were identified in both the cervical 
and breast specimens from 13 (46%) of patients. High-risk HPV 
types 16, 18, 33, and 58 were identified in 19 (70%) invasive and 
2 (100%) non-invasive breast cancer specimens (Table 1). HPV 
type 18 was the most prevalent. This compares with the preva-
lence of HPV sequences in 3 (17%) of 18 normal breast specimens 
from cosmetic surgery (Table 2) (p-value for difference = 0.001). 
The HPV 18 DNA sequences in both cervical neoplasia and later 
breast cancer are shown in Figure  1. These data demonstrate 
that (i) the sequences are virtually identical in both the cervical 
and subsequent breast cancers from the same patients and offers 
direct evidence that prior HPV cervical infection is the likely 
source of the later HPV positive breast cancer and (ii) there are 
variations in the sequences, which indicate the outcomes are valid 
and not a result of contamination. This is illustrated in Figure 2 
showing HPV, positive by in  situ PCR, in which HPV type 18 
was identified in cervical intraepithelial neoplasia grade 1 (CIN 1) 
diagnosed in a patient who later developed HPV type 18 positive 
ductal carcinoma in situ breast cancer (DCIS).
confirmation of These Data
DNA extracts from 11 cervical and breast cancer HPV positive 
specimens (as identified in the University of New South Wales 
laboratories) were independently analyzed (Annika Antonsson, 
QIMR Berghofer Medical Research Institute). HPV types 16, 18, 
and 33 were identified in 4 cervical and 2 breast specimens. The 
identification of different HPV types indicates that contamina-
tion is improbable.
cervical and Breast Pathology
The pathological characteristics of the prior cervical and later 
breast specimens from the same patient are shown in Table 1. Two 
cervical specimens were normal, 6 of 28 (21%) had HPV koilocy-
tosis (no CIN); 8 of 28 (31%) were CIN grade 1; 5 of 28 (17%) were 
CIN 2; and 7 of 28 (21%) were CIN 3. Two of the breast cancers 
TaBle 2 | Prevalence of high-risk hPV sequences, hPV e7 protein 
expression, and koilocytes in normal breast tissues, cervical precancers, 
and subsequent cancerous breast tissues from the same patients.
normal 
breast
cervical 
precancer
Breast 
Dcis
Breast 
iDc/ilc
High-risk HPV sequences 
(types 16, 18, 33, 58)
3/18 (17%) 20/25 (80%) 2/2 19/27 (70%)
HPV E7 4/18 (22%) 1/2 16/25 (64%)
Koilocytes 0/18 (0%) 27/28 (96%) 1/2 8/25 (32%)
Breast cancer developed 1–11 years after the initial cervical condition (hyperplasia with 
HPV characteristics or CIN I, II, or III).
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular 
carcinoma.
PATIENT 16
Cervix TAAGGAAGGTACATATAAAAATGATAATTTTAAGGAATATGTACGTCATGTTGAAGAA
Breast TAAGGAAGGTACATATAAAAATGACAATTTTAAGGAATATGTACGTCATGTTGAAGAA
Ref HPV58  TAAGGAAGGTACATATAAAAATGACAATTTTAAGGAATATGTACGTCATGTTGAAGAA
PATIENT 20
Cervix     TTCAGAAACTACATATAAAAATACTAACTTTAAGGAGTACCTCCGACATGGGGAGGAA
Breast         TTCAGAAACTACATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGTGATGAA
Ref HPV16    TTCAGAAACTACATATAAAAATACTAACTTTAAGGAGTACCTCCGACATGGGGAGGAA
Cervix         TGTACCTGGGCAATATGATGCTACCAAATTTAAGCAGTATAGCAGACATGTTGAGGAA
Breast    TGTACCTGGGCAATATGATGCTACCAAATTTAAGCAGTATAGCAGACATGTTGAGGAA
Ref HPV18 TGTACCTGGGCAATATGATGCTACCAAATTTAAGCAGTATAGCAGACATGTTGAGGAA
Patient 28
Cervix    TGTACCTGGGCAATATGATGCTACCAAATTTAAGCAGTATAGCAGACATGTTGAGGAA
Breast         TGTACCTGGGCAATATGATGCTACCAAATTTAAGCAGTATAGCAGACATGNTGAGGAA
Ref HPV18    TGTACCTGGGCAATATGATGCTACCAAATTTAAGCAGTATAGCAGACATGTTGAGGAA
FigUre 1 | examples of 3′ Pcr hPV Dna sequences in cervical intraepithelial neoplasia and in subsequent breast cancer in three patients. Patient 
20 was a mixture of HPV 16 and 18 extracted from different blocks. The reference sequences are HPV 16 FJ610152., HPV 18 Q902111, and HPV 58 HM639516. 
The total length of sequence (approximately 100 bases) did not show any differences to the reference sequences.
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immunohistochemistry
As shown in Tables  1 and 2, both HPV sequences and HPV 
E7 protein expression were present in 12 of 24 (50%) of breast 
cancer specimens. In 8 of 24 (33%) of breast cancer specimens, 
HPV sequences were identified but HPV E7 protein was not 
expressed. HPV E7 protein was expressed in 4 of 18 (22%) nor-
mal breast specimens from cosmetic surgery (p-value = 0.007).
HPV E7 in an HPV positive invasive breast cancer specimen is 
shown in Figure 3. The HPV E7 staining characteristics of HPV 
E7 in the CIN control specimen are virtually identical with those 
published by Faoro et al. (12). HPV E7 staining of both the cell 
nuclei and cytoplasm is common in both normal breast lobules 
(adjacent to invasive breast cancer) and in invasive breast cancer. 
We have consistently observed that with respect to IHC analyses, 
the staining by E7 antibodies is much stronger in normal breast 
tissues and benign breast tissues than in invasive cancers as is 
shown in Figure 3.
hPV Biological activity
As indicated above, HPV E7 protein was expressed in 64% of 
the breast cancer specimens (Table 2) and 22% of normal breast 
specimens from cosmetic surgery (p-value = 0.007).
Koilocytes were identified in all of the cervical specimens and 
in 9 of 28 (32%) of the breast cancers, which had later developed 
in the same patients. Typical koilocytes are shown in squamous 
epithelial cells of cervical tissue and glandular epithelial cells of 
breast cancer in the same patient in Figure 4. As koilocytes are 
specific to HPV infections and are a consequence of the influ-
ence of HPV E5 and E6 genes, the presence of koilocytes in breast 
cancer cells is a strong indicator of HPV precancerous biological 
which developed 1–11 years later were non-invasive and 26 of 28 
(93%) were invasive. Six of 28 (21%) of the invasive breast cancers 
were grade 1, 11 of 28 (39%) grade 2 and 6 of 28 (21%) grade 3.
age of Patients at Date of Diagnosis
The average age of patients at date of diagnosis of breast cancer 
following cervical pathology was 51 years (Table 1). This is on 
average 9 years younger than the average age of 60 years at diag-
nosis of all breast cancers in Australian women (p-value = 0.001). 
Eleven of 28 (39%) of the patients were 45 years or younger at the 
date of breast cancer diagnosis.
The number of years between the age of cervical and subsequent 
breast cancer diagnosis was 3.7 years for women below the age of 
50 and 9.0 years for women 50 years or over (p-value = 0.001). 
The reason for the much lower gap for younger women in years 
between cervical and later breast cancer in the same patient is 
not known.
A B
C D
A B
C D
FigUre 2 | human papilloma virus positive cervical intraepithelial neoplasia followed by breast cancer in the same patient. HPV identified by in situ 
PCR in cervical intraepithelial neoplasia grade 1 (CIN 1) diagnosed in a patient who later developed HPV positive ductal carcinoma in situ breast cancer (DCIS). Both 
were confirmed to be HPV 18 by PCR followed by sequencing. (a) HPV positive CIN 1. (B) Negative control with PCR primer omitted. (c) HPV positive ductal 
carcinoma in situ. (D) Negative control with PCR primer omitted.
January 2016 | Volume 5 | Article 2986
Lawson et al. HPVs and Young Age Breast Cancer
Frontiers in Oncology | www.frontiersin.org
activity. The histological diagnosis of koilocytes is subjective 
because they are difficult to distinguish from apoptopic epithelial 
cells, and therefore these data need to be considered with caution.
DiscUssiOn
Cohort studies are a valuable approach to the study of viruses 
and cancer because they offer insights into the natural history 
of the disease. Prospective cohort studies are usually preferred 
to case control or retrospective studies because the risk of bias is 
generally considered to be less. However, we have undertaken a 
retrospective cohort study, because it is a practical and low cost 
method of achieving sound outcomes.
We have shown that (i) high-risk HPVs are present in 70% 
of breast cancers among women who had prior HPV positive 
cervical neoplasia  –  HPV types were identical in both prior 
cervical neoplasia and later breast cancer in 46% of the patients, 
(ii) HPV E7 was expressed in 64% of invasive breast cancers, and 
(iii) HPV-associated koilocytes were identified in 32% of breast 
cancers which is an additional indicator of HPV biological activ-
ity. We have also demonstrated that HPV positive breast cancer 
following HPV-associated cervical cancer occurs significantly 
more commonly in younger age women.
Despite reviewing approximately 4,000 pathology reports 
of breast cancer specimens, only 28 (0.7%) women with breast 
cancer had prior cervical neoplasms. While this may be an under 
estimate because not all biopsy and surgical specimens would 
have been referred to the same pathology service, it suggests 
that prior HPV cervical neoplasia is associated with a very low 
prevalence of subsequent HPV positive breast cancer.
A B 
FigUre 3 | hPV e7 protein expression invasive breast cancer. (a) HPV 18 positive invasive breast cancer in a woman aged 48 years. (B) Positive control HPV 
positive cervical intraepithelial neoplasia.
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Validity of the Findings
The use of a range of techniques, namely, standard and real-time 
PCR, in situ PCR, IHC, and koilocytosis based on light micros-
copy, has given broadly similar outcomes. The identification of 
different HPV types and the sequence variations also indicates 
that the outcomes by various PCR methods are valid and are not 
due to contamination. In addition, these observations validate 
the findings of the previous studies by Hennig et  al. (2) and 
Widschwendter et  al. (3), which identified high-risk HPVs in 
both prior cervical and later breast cancer in the same patient.
Interpretation of the Findings
It is particularly noteworthy that virtually identical HPV type 
18 and HPV type 58 sequences were identified in both CIN and 
1–11 years later in breast cancer in 46% of the same subjects. This 
is compatible with the same virus infection having an oncogenic 
role in both the cervical and breast cancers in the same patients. 
HPV type 18 is the dominant HPV type in both breast and 
prostate cancers among Australian patients (14, 15). In addition, 
HPV type 18 is tropic to glandular (as distinct from squamous) 
cervical cancer cells (16). The high (62%) proportion of HPV type 
18 is very similar to the proportion of HPV type 18 identified in 
adenocarcinoma of the cervix (16).
The identification of koilocytes in 32% of the breast cancer 
specimens is of interest. This is a high proportion of koilocytes 
as compared to the identification of <5% in other series of breast 
cancers without prior HPV-associated cervical neoplasia (17). 
This may be due to a higher HPV viral load in breast cancers 
with prior cervical neoplasia. The identification of koilocytes by 
light microscopy is subjective. It is difficult to distinguish between 
true koilocytes, fixation artifacts, and apoptopic epithelial cells. 
However, koilocytes were identified in approximately one-third 
of breast cancer specimens, which were positive for HPV by 
in situ PCR, which adds validity to the histological assessments.
The observation that HPV E7 protein expression may be 
absent in HPV sequence positive breast cancer specimens is of 
interest. A possible explanation is that HPV infections may have 
an early role in breast oncogenesis. This view is supported by the 
recent findings by Ohba et al. (18) that HPV infections appear to 
enhance the biological activity of APOBEC3B genes, which are 
known to lead an increased risk of breast cancer (19).
Although it is accepted by research workers in this field that 
HPVs are present in many breast tumors, there is concern that 
the viral load is so low that HPVs may not be oncogenic in breast 
cancer (20). However, similarly, low HPV viral loads have been 
observed in some cervical cancers, which indicate that low viral 
loads of HPVs can be oncogenic (16). In addition to the role of 
HPVs in the enhancement of the biological activity of APOBEC 
genes early in breast cancer oncogenesis adds to the validity of 
this concept. Epstein–Barr virus has been identified in 68% of 
Australian invasive breast cancers and may also enhance the 
oncogenicity of HPV despite this low viral load (21).
The expression of HPV E7 proteins and HPV-associated 
koilocytes in these sets of specimens are an indication that HPVs 
in these breast specimens are biologically active and capable of 
being oncogenic. Accordingly, despite their extremely low viral 
load, HPVs appear to be biologically active and have oncogenic 
influences in some of the breast cancers in this study.
Of particular interest is the very young age of many of these 
patients. Approximately 39% of the patients with prior cervical 
neoplasia were 45 years of age or below at age of breast cancer 
diagnosis. Breast cancer in young women is often aggressive and 
FigUre 4 | hPV-associated koilocytes in cervical cin 1 and putative koilocytes in ductal carcinoma in situ breast cancer which developed 4 years 
later in the same patient then aged 48 years.
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appears to have distinct biological characteristics (22). These 
include a core set of abnormally regulated microRNAs that 
differ from microRNAs in breast cancer in older women (22). 
The young age of these patients parallels the high prevalence 
of high-risk HPV infections among young Australian women 
(8). For Australian women aged 15–40 years, the prevalence of 
cervical HPV infections prior to HPV vaccination programs was 
41% and over 50% for women under the age of 30 years (8). The 
implication is that young age breast cancer may be associated 
with high-risk HPV infections.
There has been a small but significant increase in the incidence 
among young (below age 40 years) US women of breast cancers 
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with metastases during the past three decades (23). The 5-year 
mortality rate among these young women is approximately 70%. 
This increase in serious young age breast cancers parallels the 
increase in HPV genital infections in young US women. Again 
the implication is that high-risk HPV infections may be the 
reason for the increase in breast cancer in young women.
These observations are in accord with the well-known 
bimodal peak frequencies of breast cancer at different ages of 
diagnosis (23). The first peak tends to arise early in life at around 
age 50 years and generally behaves aggressively. The second peak 
occurs later in life at around 70 years and usually follows a more 
indolent course.
Also of interest is the 3.7-year gap between age of cervical 
and breast cancer diagnosis among women aged below 50 years 
as compared with 9.0 years for women 50 years and over at age 
of breast cancer diagnosis. This is compatible with the greater 
influence of sex hormones among younger women on both 
breast cancer and HPV viral replication (24). The HPV genome 
contains sex hormone receptors and replication is enhanced in 
the presence of sex hormones (25). The HPV18 regulatory region 
contains one functional GRE sequence that interacts with the 
glucocorticoid receptor and confers hormonal activation to the 
HPV18 P105 promoter (25). This is also compatible with the 
trend to higher grades of breast cancer among younger women 
with high hormone levels.
The mode of transmission of HPV to the breast is not known. 
However, it is possible that HPVs are transmitted to the genital 
tract during sexual activities and later transmitted by white blood 
cells throughout the body, including the breasts. This hypothesis 
is based on the young age of women with HPV positive breast 
cancer and who are sexually active and have a high incidence of 
HPV cervical infections plus the repeated identification of high-
risk HPVs in white blood cells (26).
Other viruses, including mouse mammary tumor virus, 
Epstein–Barr virus, and bovine leukemia virus, may each have 
a role in breast cancer including collaborative roles with HPVs 
(21). Therefore, it is difficult to determine the proportion of 
breast cancers that may be caused by high-risk HPVs. However, 
as described above, this proportion is probably very small.
cOnclUsiOn
The findings in this study indicate that high risk for cancer 
HPVs can be associated with cervical neoplasia and subse-
quent young age breast cancer. However, these associations 
are unusual and are a very small proportion of breast cancers. 
These outcomes confirm and extend the observations of two 
similar previous studies and offer one explanation for the 
increased prevalence of serious invasive breast cancer among 
young women.
The availability and widespread use of vaccines which can 
effectively control high-risk HPV infections may result in a 
decrease of HPV-associated breast cancer and, thereby, provide 
evidence whether HPVs have a causal role in breast cancer.
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